News & Events

Otonomy Appoints Anthony J. Yost Chief Commercial Officer

SAN DIEGO, Oct. 21, 2014 (GLOBE NEWSWIRE) – Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced the appointment of Anthony J. Yost as chief commercial officer. Mr. Yost brings 30 years of experience in pharmaceutical product sales and marketing that includes building and managing commercial teams at multiple companies. “The addition of Tony to the Otonomy team is an...

read more

Otonomy Enrolls First Meniere’s Disease Patients in OTO-104 Multiple-Dose Safety Study

SAN DIEGO, Oct. 9, 2014 (GLOBE NEWSWIRE) – Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced the enrollment of the first patients in a multiple-dose safety study of OTO-104 initiated in the United Kingdom (U.K.) in patients with Ménière’s disease. The prospective, randomized, placebo-controlled study, designed to evaluate the safety of multiple doses of OTO-104,...

read more

Otonomy Added To Russell 2000(R) Index

SAN DIEGO, Oct. 1, 2014 (GLOBE NEWSWIRE) – Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that the company was added to the Russell 2000® Index as part of Russell Investments’ quarterly addition of select initial public offering (IPO) companies. Otonomy joined the index after the equity markets closed on September 30, 2014. The Russell 2000 Index measures the...

read more

Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases

Chief Medical Officer Appointed to Advance Growing Portfolio; Series A Extension Earmarked for Second Product Candidate Preclinical Development San Carlos, CA – September 30, 2014 – Allakos Inc. announced today that it has secured an additional $10 million investment from current investors to fund development of an additional therapeutic antibody. The additional financing was completed following achievement of a key, pre-specified milestone related to the company’s lead antibody program, and represents an extension of the company’s...

read more

ZS Pharma Announces Positive Top-Line Results from HARMONIZE (ZS004), a Second Phase 3 Clinical Trial of ZS-9 in Patients with Hyperkalemia

ZS-9 meets primary endpoint at all three doses tested Coppell, Texas – September 23, 2014 – ZS Pharma (Nasdaq: ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced positive top-line results from HARMONIZE (ZS004), its second Phase 3 clinical trial of ZS-9 (sodium zirconium cyclosilicate), a novel investigational treatment for hyperkalemia. Preliminary analyses of the results showed that all three doses (5g, 10g, and 15g) of once daily ZS-9 met the primary...

read more

ZS Pharma Presents New Data from ZS003 a Two Week Phase 3 Trial Demonstrating that ZS-9 Prevented Recurrence of Hyperkalemia in Heart Failure Patients on RAASi

Data Featured as Oral Presentation During a Late-Breaking Clinical Trial Session at the Heart Failure Society of America (HFSA) 18th Annual Scientific Meeting  Coppell, Texas – September 15, 2014 - ZS Pharma (Nasdaq: ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced results of a secondary analysis of ZS003, a two week pivotal Phase 3 trial of ZS-9 (sodium zirconium cyclosilicate), its investigational treatment for hyperkalemia. Hyperkalemia is a...

read more

RiverVest invests in Tryton’s $20 million funding round

By:  Brian Feldt, St. Louis Business Journal September 8, 2014 Tryton Medical, a company developing stents to treat coronary bifurcation lesions, has raised $20 million in equity from a group of investors that includes St. Louis-based RiverVest Venture Partners and the 3×5 Special Opportunity Fund. Both RiverVest and the 3X5 fund, which is co-managed by RiverVest, have participated in funding rounds for Tryton before, most recently in a $24 million equity financing round for the Durham, North Carolina-based company in early 2013.  ...

read more

RiverVest Venture Partners’ Otonomy Completes $100 Million Initial Public Offering

ST. LOUIS and SAN DIEGO (Aug. 13, 2014) – Otonomy, Inc., a RiverVest Fund II portfolio company that develops drug therapies for the inner and middle ear, announced today its $100 million initial public offering. The San Diego-based biopharma company priced 6.25 million shares of common stock at a price of $16.00 per share, which starts trading today on the NASDAQ under the symbol OTIC. Otonomy also granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stock which could increase the gross offering...

read more

Ear biotech Otonomy sets terms for $80 million IPO

Source:  IPO investment firm Renaissance Capital Otonomy, a late-stage biotech developing sustained-exposure treatments for ear diseases, announced terms for its IPO on Friday. The San Diego, CA-based company plans to raise $80 million by offering 5.3 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Otonomy would command a fully diluted market value of $315 million. Otonomy’s lead candidate treats middle ear effusion developed during tympanostomy tube placement surgery. The company plans to submit...

read more

Tryton Medical Enrolls First Patient in the EXTENDED Access Registry A Single Arm Study Designed to Support FDA Submission for US Approval

Durham, N.C. – July 28, 2014 – Tryton Medical, Inc., the leading developer of stents to treat bifurcation lesions, announced that the first patient has been enrolled in the EXTENDED Access Registry (Tryton IDE XA registry), a single arm study of its Tryton Side Branch Stent. The Tryton IDE XA registry is designed to support FDA submission for US approval and is expected to enroll 133 patients from Europe and the United States. Indulis Kumsars, M.D. of P. Stradins University Hospital, Latvian Centre of Cardiology enrolled the first...

read more